Do analysts prefer STVN or FTRE?

Fortrea has a consensus target price of $22.00, suggesting a potential upside of 10.00%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 Fortrea 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to STVN or FTRE?

In the previous week, Stevanato Group and Stevanato Group both had 8 articles in the media. Fortrea's average media sentiment score of 0.50 beat Stevanato Group's score of 0.40 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SHC or FTRE more profitable?

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 13.44% 40.12% 7.55% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to SHC or FTRE?

In the previous week, Fortrea had 7 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Fortrea and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.59 beat Fortrea's score of 0.50 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FTRE or ADPT?

In the previous week, Fortrea had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.52 beat Fortrea's score of 0.50 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or FTRE?

In the previous week, Fortrea had 7 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Fortrea and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.88 beat Fortrea's score of 0.50 indicating that Alamar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or FTRE?

In the previous week, Fortrea had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Fortrea and 2 mentions for Maravai LifeSciences. Fortrea's average media sentiment score of 0.50 beat Maravai LifeSciences' score of 0.00 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fortrea (FTRE) Competitors

$20.00 +0.60 (+3.09%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$19.98 -0.02 (-0.08%)

As of 10/2/2026 07:30 PM Eastern

Compare

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

Should you buy Fortrea stock or one of its competitors? Fortrea's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Fortrea compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Fortrea has a consensus target price of $22.00, suggesting a potential upside of 10.00%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Stevanato Group and Stevanato Group both had 8 articles in the media. Fortrea's average media sentiment score of 0.50 beat Stevanato Group's score of 0.40 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a net margin of 10.99% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Fortrea	-3.18%	10.72%	2.17%

Stevanato Group has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.56	€158.21M	€0.56	36.07
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A

Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Summary

Stevanato Group beats Fortrea on 8 of the 14 factors compared between the two stocks.

How does Fortrea compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Fortrea had 7 more articles in the media than Sotera Health. MarketBeat recorded 8 mentions for Fortrea and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.59 beat Fortrea's score of 0.50 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Sotera Health shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Fortrea	-3.18%	10.72%	2.17%

Sotera Health has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Sotera Health currently has a consensus price target of $21.50, suggesting a potential upside of 18.00%. Fortrea has a consensus price target of $22.00, suggesting a potential upside of 10.00%. Given Sotera Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sotera Health is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sotera Health has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.47	$77.94M	$0.57	31.96
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A

Summary

Sotera Health beats Fortrea on 13 of the 16 factors compared between the two stocks.

How does Fortrea compare to Adaptive Biotechnologies?

Fortrea (NASDAQ:FTRE) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Fortrea currently has a consensus target price of $22.00, indicating a potential upside of 10.00%. Adaptive Biotechnologies has a consensus target price of $28.94, indicating a potential upside of 2.07%. Given Fortrea's higher probable upside, equities analysts plainly believe Fortrea is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Fortrea had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Fortrea and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.52 beat Fortrea's score of 0.50 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 0.7% of Fortrea shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fortrea has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Adaptive Biotechnologies has lower revenue, but higher earnings than Fortrea. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A
Adaptive Biotechnologies	$308.08M	14.69	-$59.50M	-$0.41	N/A

Fortrea has a net margin of -3.18% compared to Adaptive Biotechnologies' net margin of -20.73%. Fortrea's return on equity of 10.72% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Summary

Adaptive Biotechnologies beats Fortrea on 9 of the 16 factors compared between the two stocks.

How does Fortrea compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Alamar Biosciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	32.13	-$29.82M	-$1.96	N/A
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A

Alamar Biosciences presently has a consensus target price of $31.80, indicating a potential downside of 7.45%. Fortrea has a consensus target price of $22.00, indicating a potential upside of 10.00%. Given Fortrea's higher probable upside, analysts clearly believe Fortrea is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alamar Biosciences has a net margin of 0.00% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Fortrea had 7 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Fortrea and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.88 beat Fortrea's score of 0.50 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fortrea beats Alamar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Fortrea compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Maravai LifeSciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	11.04	-$130.77M	-$0.52	N/A
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A

Maravai LifeSciences has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 0.7% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Fortrea had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Fortrea and 2 mentions for Maravai LifeSciences. Fortrea's average media sentiment score of 0.50 beat Maravai LifeSciences' score of 0.00 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences currently has a consensus price target of $6.83, indicating a potential downside of 13.50%. Fortrea has a consensus price target of $22.00, indicating a potential upside of 10.00%. Given Fortrea's stronger consensus rating and higher probable upside, analysts clearly believe Fortrea is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Fortrea has a net margin of -3.18% compared to Maravai LifeSciences' net margin of -37.07%. Fortrea's return on equity of 10.72% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Fortrea	-3.18%	10.72%	2.17%

Summary

Fortrea beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTRE vs. The Competition

Export

Metric	Fortrea	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$10.57B	$7.14B	$13.18B
Dividend Yield	N/A	1.45%	2.53%	16.78%
P/E Ratio	-21.98	74.99	275.68	26.04
Price / Sales	0.71	459.98	663.82	108.79
Price / Cash	1.96	26.96	77.60	51.75
Price / Book	3.28	6.85	10.93	6.31
Net Income	-$986.20M	$57.48B	$3.51B	$362.16M
7 Day Performance	0.55%	2.53%	-2.00%	-1.66%
1 Month Performance	7.41%	8.43%	-6.15%	-4.50%
1 Year Performance	111.64%	32.93%	7.44%	2.06%

Fortrea Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTRE Fortrea	2.8145 of 5 stars	$20.00 +3.1%	$22.00 +10.0%	+108.3%	$1.84B	$2.68B	N/A	14,300	News Coverage Analyst Upgrade
STVN Stevanato Group	2.7118 of 5 stars	€21.47 +0.3%	N/A	-24.1%	€6.50B	€1.34B	38.34	6,010	News Coverage Insider Trade
SHC Sotera Health	3.2226 of 5 stars	$18.45 +0.6%	$21.50 +16.5%	+14.7%	$5.23B	$1.16B	32.37	3,000	Positive News
ADPT Adaptive Biotechnologies	1.4621 of 5 stars	$28.51 -3.1%	$28.06 -1.6%	+99.1%	$4.70B	$276.98M	N/A	624	Analyst Forecast
ALMR Alamar Biosciences	1.7654 of 5 stars	$32.61 -0.6%	$31.80 -2.5%	N/A	$2.28B	$74.21M	N/A	222

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTRE) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortrea (FTRE) Competitors

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Fortrea compare to Stevanato Group?

Summary

How does Fortrea compare to Sotera Health?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Summary

How does Fortrea compare to Alamar Biosciences?

Summary

How does Fortrea compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortrea (FTRE) Competitors

FTRE vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Fortrea compare to Stevanato Group?

Do analysts prefer STVN or FTRE?

Does the media refer more to STVN or FTRE?

Is STVN or FTRE more profitable?

Which has higher valuation and earnings, STVN or FTRE?

Which has more volatility and risk, STVN or FTRE?

Summary

How does Fortrea compare to Sotera Health?

Does the media refer more to SHC or FTRE?

Do institutionals & insiders believe in SHC or FTRE?

Is SHC or FTRE more profitable?

Which has more volatility and risk, SHC or FTRE?

Do analysts prefer SHC or FTRE?

Which has preferable earnings & valuation, SHC or FTRE?

Summary

How does Fortrea compare to Adaptive Biotechnologies?

Do analysts prefer FTRE or ADPT?

Does the media favor FTRE or ADPT?

Do institutionals and insiders have more ownership in FTRE or ADPT?

Which has more volatility & risk, FTRE or ADPT?

Which has preferable valuation and earnings, FTRE or ADPT?

Is FTRE or ADPT more profitable?

Summary

How does Fortrea compare to Alamar Biosciences?

Which has higher earnings & valuation, ALMR or FTRE?

Do analysts recommend ALMR or FTRE?

Is ALMR or FTRE more profitable?

Does the media prefer ALMR or FTRE?

Summary

How does Fortrea compare to Maravai LifeSciences?

Which has preferable valuation & earnings, MRVI or FTRE?

Which has more volatility and risk, MRVI or FTRE?

Do insiders and institutionals have more ownership in MRVI or FTRE?

Does the media refer more to MRVI or FTRE?

Do analysts recommend MRVI or FTRE?

Is MRVI or FTRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools